

Special Issue

PARPs in Cancer

Message from the Guest Editor

The key role of Poly (ADP-ribose) polymerases (PARPs) in the DNA damage response to single-stranded breaks has been recognized for several decades. However, interest in PARPs as a target in cancer therapy was greatly increased with the discovery that PARP inhibition is synthetically lethal with defects in homologous recombination, most notably in breast and ovarian cancers with loss of BRCA function. This led to the rapid development and regulatory approval of several PARP inhibitors that are now established in clinical use. Despite this early success, there are still major unanswered questions about the role of PARPs in cancer, and how to further develop PARP inhibitors beyond their use in BRCA-deficient disease. This Special Issue will highlight both the roles of PARP family members in cancer and approaches that aim to expand our biological understanding and future clinical potential of PARP inhibitors either as a monotherapy or in combination with established or emerging anti-cancer agents.

Guest Editor

Dr. Anderson Ryan

Department of Oncology, University of Oxford, Old Road Campus
Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK

Deadline for manuscript submissions

closed (1 August 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/54909

Cancers

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)